Quest Medical
This article was originally published in The Gray Sheet
Executive Summary
Manufacturer of cardiovascular surgery, oncology and IV therapy products expects to report a net loss of approximately $1.1 mil. for the fourth quarter ended Dec. 31. The loss is "primarily due to a one-time, non-cash, pre-tax charge of approximately $1.25 mil." related to the write-off of the assets of Clini-Therm Corporation, which was acquired in July 1991 through that firm's chapter seven foreclosure proceedings ("The Gray Sheet" July 15, 1991, p. 11). Revenue for the quarter is expected to be approximately $3.4 mil., "slightly below earlier expectations." Quest notes in a release that it has decided "not to invest further" in its Prostek 3000 hyperthermia device for heat treatment of benign prostatic hyperplasia (BPH), although the firm remains "optimistic" about the commercial potential of the technology. The firm cites more appealing R&D investments in the cardiovascular market and a costly and time-consuming PMA process as the reason for shelving the project. Among the firm's cardiovascular product development efforts is a myocardial protection system for use during cardiovascular surgery. Quest hopes to start beta testing of the system before the end of the year.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.